Carfilzomib induced cardiotoxicity in a multiple myeloma patient

Proteasome inhibitors such as carfilzomib are indicated in multiple myeloma patients showing relapse and/or refractoriness of clonal activity. However, this therapy has been associated with a significant incidence of cardiotoxicity, especially in patients with known cardiovascular risk factors. Here...

Descripción completa

Detalles Bibliográficos
Autores principales: Méndez-Toro, Arnold, Díaz-Brochero, Cándida, Acosta-Gutiérrez, Estivalis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487899/
https://www.ncbi.nlm.nih.gov/pubmed/32944287
http://dx.doi.org/10.1186/s40959-020-00074-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487899/
https://www.ncbi.nlm.nih.gov/pubmed/32944287
http://dx.doi.org/10.1186/s40959-020-00074-8

Ejemplares similares